Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William Peters sold 8,180 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, August 7th. The shares were sold at an average price of $22.48, for a total transaction of $183,886.40. Following the transaction, the chief financial officer owned 172,846 shares in the company, valued at approximately $3,885,578.08. This trade represents a 4.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Trading Up 0.5%

Shares of AMPH stock opened at $20.42 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $16.65 and a 52-week high of $31.26. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. The firm has a market capitalization of $868.67 million, a PE ratio of 12.08, a PEG ratio of 4.29 and a beta of 0.89. The stock has a fifty day simple moving average of $19.74 and a two-hundred day simple moving average of $21.28.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The business had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $32,000. Farther Finance Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 46.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 24.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in shares of Amphastar Pharmaceuticals by 410.1% in the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after purchasing an additional 1,944 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Amphastar Pharmaceuticals by 263.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock worth $82,000 after purchasing an additional 2,596 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Barclays lowered their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Wells Fargo & Company lifted their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $22.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.